trending Market Intelligence /marketintelligence/en/news-insights/trending/HOCExAwdhAmcLxlXF5XsmA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Sapporo Clinical Laboratory fiscal Q4 profit falls YOY

Amazon e-commerce sales soar amid COVID-19

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Sapporo Clinical Laboratory fiscal Q4 profit falls YOY

Sapporo Clinical Laboratory Inc. said its normalized net income for the fiscal fourth quarter ended March 31 was ¥49.76 per share, a decrease from ¥50.59 per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥173.1 million, a decrease from ¥176.3 million in the year-earlier period.

The normalized profit margin climbed to 3.9% from 3.9% in the year-earlier period.

Total revenue decreased on an annual basis to ¥4.40 billion from ¥4.51 billion, and total operating expenses fell on an annual basis to ¥4.14 billion from ¥4.24 billion.

Reported net income decreased 33.7% from the prior-year period to ¥136.0 million, or ¥39.09 per share, from ¥205.0 million, or ¥58.84 per share.

For the year, the company's normalized net income totaled ¥179.47 per share, a gain of 21.9% from ¥147.24 per share in the prior year.

Normalized net income was ¥624.4 million, a rise of 11.6% from ¥559.4 million in the prior year.

Full-year total revenue grew on an annual basis to ¥17.53 billion from ¥17.17 billion, and total operating expenses grew on an annual basis to ¥16.55 billion from ¥16.30 billion.

The company said reported net income increased on an annual basis to ¥590.0 million, or ¥169.59 per share, in the full year, from ¥573.0 million, or ¥150.83 per share.

As of June 29, US$1 was equivalent to ¥102.64.